Roche’s medicine Avastin plus chemotherapy improved survival in women with advanced cervical cancer, compared to chemotherapy alone
2 June 2013 | By Roche
Results of study GOG240...
List view / Grid view
2 June 2013 | By Roche
Results of study GOG240...
1 July 2014 | By Merck
Merck planning regulatory submissions in the U.S. for EMEND® in pediatric setting including new suspension formulation in second half of 2014...
20 September 2021 | By Anna Begley (European Pharmaceutical Review)
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
17 November 2014 | By Roche
Avastin plus chemotherapy reduced the risk of the disease worsening by 62 percent compared to chemotherapy alone in a Phase III study...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events…
11 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months and caused fewer side effects...
9 July 2015 | By Victoria White
Researchers have been studying what happens when different chemotherapy drugs come in contact with the silver coating on catheters with surprising results...
28 May 2020 | By Hannah Balfour (European Pharmaceutical Review)
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
6 August 2021 | By Anna Begley (European Pharmaceutical Review)
Phase III trial of Libtayo® (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
6 May 2015 | By
Acacia Pharma has announced positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV)...
3 June 2015 | By Victoria White
The EC has approved Akynzeo for use in the European Union for the prevention of acute and delayed chemotherapy-induced nausea and vomiting...
8 April 2015 | By Victoria White
The EU has approved Avastin in combination with chemotherapy for the treatment of persistent, recurrent or metastatic carcinoma of the cervix...
2 March 2015 | By Roche
Combination of Avastin and chemotherapy would be the first new treatment in advanced cervical cancer to extend life in nearly a decade...